Minerva Neurosciences Inc/ US6033802058 /
2024-04-25 9:59:53 PM | Chg. -0.0900 | Volume | Bid1:00:00 PM | Ask1:00:00 PM | High | Low |
---|---|---|---|---|---|---|
2.4300USD | -3.57% | 5,770 Turnover: 11,567.7145 |
2.4200Bid Size: 600 | 2.4600Ask Size: 100 | 2.5050 | 2.4300 |
GlobeNewswire
02-27
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Rolupe...
GlobeNewswire
02-22
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Upd...
GlobeNewswire
2023-11-07
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
GlobeNewswire
2022-03-01
Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates
GlobeNewswire
2022-02-28
Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia B...
GlobeNewswire
2021-11-08
Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates
GlobeNewswire
2021-11-03
Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of...
GlobeNewswire
2021-11-01
Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on Novembe...
GlobeNewswire
2021-09-30
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and...
GlobeNewswire
2021-09-08
Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and...
GlobeNewswire
2021-07-26
Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August...
GlobeNewswire
2021-06-10
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
GlobeNewswire
2021-05-28
Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference
GlobeNewswire
2021-05-12
Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates
GlobeNewswire
2021-05-11
Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment o...
GlobeNewswire
2021-05-05
Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12,...
GlobeNewswire
2021-03-08
Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business...
GlobeNewswire
2021-03-01
Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Busine...
GlobeNewswire
2021-02-06
MINERVA FINAL DEADLINE NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Minerva Neurosciences,...